Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It's easy to see why investors might assume that early-stage gene-editing companies like CRISPR Therapeutics (NASDAQ: CRSP) are too inscrutable to approach. In fact, smart investors know (at least) three key things about this business, and you should too -- especially if you're considering purchasing shares sometime soon. CRISPR has a few partners, but its most important one by far is Vertex Pharmaceuticals (NASDAQ: VRTX).
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $319.98, marking a -0.46% move from the previous day.